New hope for saving nerves in aggressive ear cancer
NCT ID NCT07370337
Summary
This study is testing a combination of chemotherapy and an immunotherapy drug (tislelizumab) given before surgery for advanced squamous cell carcinoma of the ear canal. The goal is to see if this approach can shrink tumors effectively and make surgery safer by helping to preserve important nearby nerves and blood vessels. The trial will enroll about 50 adults with this specific type of locally advanced ear cancer who have not had prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF EXTERNAL AUDITORY CANAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Li Wang
RECRUITINGShanghai, Shanghai Municipality, 200031, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.